Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Dermatologic 2Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Rhabdomyosarcoma 1Recurrence 1Neuroblastoma 1Medulloblastoma 1Hepatoblastoma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 14Filgrastim 13Magnetic Resonance Spectroscopy 9Cyclophosphamide 7Carboplatin 7Peripheral Blood Stem Cell Transplantation 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Etoposide 6X-Rays 5Topotecan 5Thiotepa 5Phantoms, Imaging 5Busulfan 5Biopsy 5Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Melphalan 4Ifosfamide 4sargramostim 3palbociclib 3olaparib 3etoposide phosphate 3Surgical Procedures, Operative 3Paclitaxel 3ulixertinib 2trioctyl phosphine oxide 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × sonidegib × Sarcoma × Clear all
NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Novartis

Phase 1/2 Completed
76 enrolled 18 charts
CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡